Home > Dermatology > AAD 2022 > What’s Hot in Rare Diseases > JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

Presented By
Prof. William Damsky, Yale School of Medicine, USA
Presented by
William Damsky
Conference
AAD 2022
At present, no approved therapies exist for cutaneous manifestations of sarcoidosis and so the medical need for an effective treatment is high. As many cytokines are involved in the pathogenesis signal via the JAK/STAT pathway, JAK inhibitors might show efficacy in this indication. Sarcoidosis is an inflammatory disorder of unknown cause characterised by granuloma formation in affected organs, most often in the lungs [1]. It develops in genetically predisposed individuals. The disease course is highly variable and difficult to predict. The typical T cell accumulation indicates that the inflammatory response seen in sarcoidosis is induced by specific antigens. Diagnosis is difficult and symptoms depend on the affected organs. Prof. William Damsky (Yale School of Medicine, CT, USA) pointed out that sarcoidosis can affect nearly any organ, but that lungs and lymph nodes are most frequently affected [2]. Sarcoidosis can be difficult to treat, and prednisone is...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on